Application of adoptive cell therapy in malignant melanoma

Abstract

Abstract Cutaneous melanoma is one of the most aggressive skin cancers originating from skin pigment cells. Patients with advanced melanoma suffer a poor prognosis and generally cannot benefit well from surgical resection and chemo/target therapy due to metastasis and drug resistance. Thus, adoptive cell therapy (ACT), employing immune cells with specific tumor-recognizing receptors, has emerged as a promising therapeutic approach to display on-tumor toxicity. This review discusses the application, efficacy, limitations, as well as future prospects of four commonly utilized approaches -including tumor-infiltrating lymphocytes, chimeric antigen receptor (CAR) T cell, engineered T-cell receptor T cells, and chimeric antigen receptor NK cells- in the context of malignant melanoma.

Keywords

• Adoptive Cell Therapy
• T-cell Receptors
• Chimeric Antigen Receptors (CARs)-T cell
• Natural Killer (NK) Cells
• Tumor-infiltrating Lymphocytes
• Malignant Melanoma